NEWS DETAIL

Syndax announced SAVE data published in the Journal of Clinical Oncology on Revuforj® (revumenib) in combination with decitabine/cidazaril and venetoclax for the treatment of relapsed/refractory NPM1m, KMT2Ar, and NUP98r AML. —GlobeNewswire

Syndax announced that it has published SAVE data in the *Journal of Clinical Oncology* on Revuforj® (revumenib) in combination with decitabine/cidazolidine and venetoclax for the t…

Medical Information July 2, 2026

该文章暂未提取到完整正文，已从资讯列表和商品关联资讯中自动隐藏。你可以返回文章列表继续浏览其他内容。

المنتجات المرتبطة بهذا المقال

تمت مطابقة هذه المنتجات تلقائيا استنادا الى عنوان المقال وملخصه ومحتواه.

الاسئلة الشائعة

Which products are related to this article?

The system matched these relevant products from the article content: شراء لوسيوس ريفومينيب عبر الإنترنت لوسيوس فينيتوكلاكس – اشترِ عبر الإنترنت فيكلادكس فينيتوكلاكس 100 ملغ.

How can I view the medicines discussed in this article?

Use the related product cards below the article to review available specifications, prices, product information, and reviews.

Does this article replace advice from a doctor or pharmacist?

No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.

Syndax announced SAVE data published in the *Journal of Clinical Oncology* on Revuforj® (revumenib) in combination with decitabine/cidazaril and venetoclax for the treatment of relapsed/refractory NPM1m, KMT2Ar, and NUP98r AML. —GlobeNewswire

المنتجات المرتبطة بهذا المقال

شراء لوسيوس ريفومينيب عبر الإنترنت

لوسيوس فينيتوكلاكس – اشترِ عبر الإنترنت

فيكلادكس فينيتوكلاكس 100 ملغ

الاسئلة الشائعة

Syndax announced SAVE data published in the Journal of Clinical Oncology on Revuforj® (revumenib) in combination with decitabine/cidazaril and venetoclax for the treatment of relapsed/refractory NPM1m, KMT2Ar, and NUP98r AML. —GlobeNewswire